Medetomidine
Medetomidine Hydrochloride
Also known as: Domitor · Dorbene · Dormilan · Medetor · Sedastart · Sedator · Sededorm · MPV-785 · Medetomidine hydrochloride
Reviewed by the VetSheet Veterinary TeamUpdated Apr 5, 2026Evidence-based veterinary reference
Audited v13 dosing evidence
Structured calculator evidenceRefractory seizures (extra-label)
Verified clinician required
NA
Governing clinical context (7)
- 1. Medetomidine dosages depend on the combination of drugs used and the dosage(s) of the other drug(s). Dosage adjustments will also need to be made to account for the degree of desired sedation; type, duration, and pain level of the procedure, and patient temperament and body weight/size.
- 3. Premedication with medetomidine will significantly reduce the dose of the induction agent required and will reduce volatile anesthetic requirements for maintenance anesthesia. All anesthetic agents used for induction or maintenance of anesthesia should be administered to effect.
- 4. For all dosages, the low end of the dose range is generally appropriate for IV administration, whereas the mid-upper range is most appropriate for IM or SC administration. Higher dosages will provide more profound sedation and analgesia.
- 5. When SC administration is used, the speed of sedation is slower, and the level of sedation is lighter and inconsistent. For more predictable sedation, IM or IV administration is recommended.
- 6. The effects of medetomidine can be reversed with atipamezole.
- It is most often dosed by volume at ½ or same volume of medetomidine that was administered and given IM. See Atipamezole.
- The commercially available injection should be stored at room temperature (15°C-30°C [59°F-86°F]) and protected from freezing. Use within 28 days of first vial puncture.
Reviewed non-calculator evidence (1)
Evidence only — not for automatic calculation
Light sedation (often also used for pre-anesthesia)
a) Light sedation (often also used for pre-anesthesia): 5 – 20 µg/kg IM, IV, SC 18
Governing clinical context (7)
- 1. Medetomidine dosages depend on the combination of drugs used and the dosage(s) of the other drug(s). Dosage adjustments will also need to be made to account for the degree of desired sedation; type, duration, and pain level of the procedure, and patient temperament and body weight/size.
- 3. Premedication with medetomidine will significantly reduce the dose of the induction agent required and will reduce volatile anesthetic requirements for maintenance anesthesia. All anesthetic agents used for induction or maintenance of anesthesia should be administered to effect.
- 4. For all dosages, the low end of the dose range is generally appropriate for IV administration, whereas the mid-upper range is most appropriate for IM or SC administration. Higher dosages will provide more profound sedation and analgesia.
- 5. When SC administration is used, the speed of sedation is slower, and the level of sedation is lighter and inconsistent. For more predictable sedation, IM or IV administration is recommended.
- 6. The effects of medetomidine can be reversed with atipamezole.
- It is most often dosed by volume at ½ or same volume of medetomidine that was administered and given IM. See Atipamezole.
- The commercially available injection should be stored at room temperature (15°C-30°C [59°F-86°F]) and protected from freezing. Use within 28 days of first vial puncture.
Doses are a clinical reference for licensed veterinary professionals. Always confirm against the current label and the individual patient.
Overview
Medetomidine is a potent, synthetic alpha-2 adrenergic agonist widely used in veterinary medicine for its profound sedative, analgesic, and muscle-relaxant properties.
Key clinical features include:
- Biphasic cardiovascular response: Initial peripheral vasoconstriction leads to transient hypertension, followed by a reflex bradycardia and subsequent normotension or mild hypotension.
- Reversibility: Its effects can be rapidly and completely reversed using specific alpha-2 antagonists like atipamezole.
- Stereochemistry: Medetomidine is a racemic mixture of two stereoisomers. The active enantiomer is dexmedetomidine, which has largely replaced racemic medetomidine in many modern veterinary markets.
- Synergism: Highly synergistic with opioids, ketamine, and other anesthetic agents, allowing for significant dose reductions of concurrent anesthetics (MAC-sparing effect).
Clinical Pearl: While it provides excellent somatic and visceral analgesia, the sedative effects typically outlast the analgesic effects. Patients may suddenly arouse if stimulated by loud noises or rough handling, even if they appear deeply sedated.
Mechanism of action
Medetomidine produces its effects by binding to and activating pre- and postsynaptic alpha-2 adrenergic receptors in the central and peripheral nervous systems.
- Central Nervous System: Activation of alpha-2 receptors in the locus coeruleus → inhibition of adenylyl cyclase → decreased cAMP → efflux of potassium (hyperpolarization) → decreased release of norepinephrine. This suppression of sympathetic outflow results in profound sedation, anxiolysis, and analgesia.
- Cardiovascular System: Activation of peripheral alpha-1 and alpha-2b receptors in vascular smooth muscle → profound vasoconstriction → increased systemic vascular resistance (hypertension) → baroreceptor-mediated increased vagal tone → reflex bradycardia.
- Endocrine/Metabolic: Inhibits insulin release from pancreatic beta cells → transient hyperglycemia. Decreases antidiuretic hormone (ADH) release → increased diuresis.
Medetomidine is highly selective, with an alpha-2:alpha-1 selectivity ratio of 1620:1 (approximately 10 times more specific than xylazine).
Safety & warnings
Contraindications
- Cardiac disease
- Respiratory disorders
- Liver or kidney diseases
- Shock or severe debilitation
- Animals stressed due to heat, cold, or fatigue
- Pregnancy (insufficient safety data; use only if benefits clearly outweigh risks)
- Cardiovascular disease
- Systemic disease
- Geriatric patients
- Pregnant animals
- Conditions where vomiting is contraindicated (e.g., gastrointestinal foreign body, raised intraocular pressure)
- Diabetes mellitus
Adverse effects
- Bradycardia (often profound)
- Atrioventricular (AV) blocks
- Decreased respiratory rate and potential apnea
- Hypothermia
- Increased urination (diuresis)
- Vomiting (especially in cats)
- Pain on intramuscular injection
- Blanched or cyanotic mucous membranes (due to peripheral vasoconstriction)
- Rarely: prolonged sedation, paradoxical excitation, hypersensitivity, death from circulatory failure
- Decreased cardiac output
- Initial hypertension followed by normotension/hypotension
- Vomiting (especially common after IM administration)
- Diuresis (due to ADH suppression)
- Transient hyperglycemia (due to decreased insulin)
- Mydriasis
- Decreased intraocular pressure
- Spontaneous arousal from deep sedation
Precautions
- Agitated Patients: Dogs that are extremely agitated or excited may have a decreased response due to high circulating catecholamines overriding the receptor. Allow dogs to rest quietly before administration. Do not re-dose if they fail to respond.
- Age Extremes: Use with extreme caution in very young or geriatric animals due to reduced cardiovascular reserve.
- Hematologic: Medetomidine can inhibit ADP-induced platelet aggregation.
- Reversal: Treat medetomidine-induced bradycardia or excessive sedation with atipamezole rather than anticholinergics.
Drug interactions
Controversial. Using anticholinergics to treat medetomidine-induced bradycardia can lead to severe hypertension, increased myocardial work, and arrhythmias. Concomitant use is generally discouraged, especially at higher medetomidine doses (>20 mcg/kg).
Synergistic enhancement of sedation and analgesia. Adverse cardiovascular and respiratory effects may also be pronounced. Reduced dosages and careful monitoring are advised.
When used after medetomidine, severe hypoxemia may occur. Significant dosage reductions of propofol are required along with adequate respiratory monitoring.
May reverse the effects of medetomidine, but atipamezole is the preferred and more specific reversal agent.
Significantly reduces the dose required for induction and maintenance of anesthesia.
Reduces the dose required to maintain anesthesia by up to 70%.
Contraindicated; may cause severe cardiovascular complications.
Synergistic sedation and analgesia (beneficial interaction).
Monitoring
- Level of sedation and analgesia
- Heart rate and rhythm (ECG recommended in high-risk patients)
- Body temperature (monitor for hypothermia)
- Respiratory rate and depth
- Pulse oximetry (SpO2)
- Heart rate and rhythm (bradycardia is expected, but monitor for severe arrhythmias)
- Blood pressure (initial hypertension followed by normotension/hypotension)
- Oxygen saturation (SpO2)
- Body temperature (risk of hypothermia due to reduced metabolic rate and peripheral vasoconstriction)
- Depth of sedation
Pharmacokinetics
Half-life
Absorption
Rapid onset after IV (5 minutes) or IM (10-15 minutes) injection. SC absorption is unreliable. Can be absorbed via oral mucosa (sublingually) but efficacy may be lower than IM.
Distribution
Highly lipophilic, allowing rapid penetration of the blood-brain barrier to exert central effects.
Metabolism
Undergoes extensive hepatic biotransformation.
Elimination
Metabolites are primarily excreted via the kidneys.
Overdose
Single doses of up to 5X (IV) and 10X (IM) have been tolerated in dogs, though severe adverse effects (profound bradycardia, AV blocks, respiratory depression) can occur. Death has occurred rarely in dogs (1 in 40,000) receiving 2X doses.
Important: Treatment of medetomidine-induced bradycardia with anticholinergic agents (atropine or glycopyrrolate) is not recommended due to the risk of severe hypertension, increased myocardial oxygen demand, and arrhythmias.
Atipamezole (an alpha-2 antagonist) is the safest and most effective choice to reverse medetomidine-induced cardiovascular and sedative effects.
Available products
Formulations
- Injection: 1 mg/mL in 10 mL multidose vials
- Injectable: 1 mg/ml solution
Veterinary
- Medetomidine HCl for Injection: 1 mg/mL in 10 mL multidose vials (Domitor®)
- Domitor 1 mg/ml solution for injection
- Dorbene 1 mg/ml solution for injection
- Dormilan 1 mg/ml solution for injection
- Medetor 1 mg/ml solution for injection
- Sedastart 1 mg/ml solution for injection
- Sedator 1 mg/ml solution for injection
- Sededorm 1 mg/ml solution for injection
Regulatory status
Classified as POM-V.
Classified as POM-V.
No regulatory data for: 🇺🇸 US · 🇭🇰 HK · 🇹🇼 TW · 🇯🇵 JP · 🇰🇷 KR · 🇦🇺 AU
Storage & stability
Store commercially available injection at room temperature (15-30°C) and protect from freezing.
Client information
- Professional Use Only: This drug is a potent sedative and anesthetic adjunct that should be administered and monitored exclusively by veterinary professionals.
- Expected Appearance: While sedated, your pet's heart rate will drop significantly, and their gums may appear pale or slightly blue. This is an expected effect of the drug and is closely monitored by the veterinary team.
- Keep Quiet: Even though your pet appears deeply asleep, sudden loud noises or rough handling can startle them awake. Keep the environment calm and quiet as they recover.
- Reversal: The veterinarian may give a "reversal agent" (atipamezole) to wake your pet up quickly and smoothly after the procedure.
- At-Risk Pets: Ensure your veterinarian is aware of any pre-existing heart, liver, or kidney conditions, or if your pet is pregnant, as this drug may not be safe in these situations.
VetSheet drug reference is intended for licensed veterinary professionals as a clinical decision-support aid, not a substitute for professional judgement or the manufacturer’s current label.